For example, two versions of a VEGF × Ang2 CrossMabCH1-CL are currently being evaluated in clinical trials: (1) RG7221 (Vanucizumab), one VEGF × Ang2 CrossMabCH1-CL, in Phase 1 in patients with cancers (NCT01688206) and (2) RG7716, the other tailor-made VEGF × Ang2 CrossMabCH1-CL, in Phase 2 trials for patients with macular degeneration (NCT02484690). Here, VEGFA is linked to macular degeneration.